TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.


Options:
A: Arm Label: ofatumumab + chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: chlorambucil, tablets, Drug: ofatumumab (GSK1841157) infusion | Arm Label: chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil, tablets | Intervention Type: DRUG; Name: chlorambucil, tablets; Assigned to Arm(s): chlorambucil, ofatumumab + chlorambucil | Intervention Type: DRUG; Name: ofatumumab (GSK1841157) infusion; Assigned to Arm(s): ofatumumab + chlorambucil
B: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
C: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
D: Arm Label: Active Comparator 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 500mg, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Active Comparator 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 1000mg, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Ofatumumab 500mg; Assigned to Arm(s): Active Comparator 1 | Intervention Type: DRUG; Name: Ofatumumab 1000mg; Assigned to Arm(s): Active Comparator 2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Active Comparator 1, Active Comparator 2 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Active Comparator 1, Active Comparator 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ParkFit Study; Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease
Brief Summary: Patients with Parkinson's disease (PD) are heavily inclined towards a sedentary lifestyle. This is caused by a combination of physical impairments and cognitive dysfunction. However, regular physical activity in PD is highly desirable, for two reasons. First, physical activity has positive generic effects in preventing complications such as cardiovascular diseases, type II diabetes mellitus, osteoporosis and certain cases of cancer. Secondly, physical activity has additional disease-specific merits in PD such as depression, sleep disturbances and constipation. These effects lead to raised quality of life. Furthermore, animal studies suggest that physical activity could slow down disease progression.

Simply informing patients about the importance of physical activity is not enough to initiate and maintain an adequate level of physical activity. We propose to develop a physical activity promoting program for sedentary patients with PD in order to raise their level of daily physical activity.

Objective: The first aim of the study is to investigate whether a physical activity promotion program will result in an increase in physical activity in sedentary patients with PD.

The second aim is to demonstrate an increase in physical fitness and quality of life.


Options:
A: Arm Label: Droxidopa; Type: EXPERIMENTAL; Interventions: Drug: Droxidopa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Droxidopa; Assigned to Arm(s): Droxidopa | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: IPX066; Type: EXPERIMENTAL; Interventions: Drug: IPX066, Drug: IR CD-LD | Arm Label: IR CD-LD; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPX066, Drug: IR CD-LD | Intervention Type: DRUG; Name: IPX066; Assigned to Arm(s): IPX066, IR CD-LD | Intervention Type: DRUG; Name: IR CD-LD; Assigned to Arm(s): IPX066, IR CD-LD
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ParkFit Study; Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease
Brief Summary: Patients with Parkinson's disease (PD) are heavily inclined towards a sedentary lifestyle. This is caused by a combination of physical impairments and cognitive dysfunction. However, regular physical activity in PD is highly desirable, for two reasons. First, physical activity has positive generic effects in preventing complications such as cardiovascular diseases, type II diabetes mellitus, osteoporosis and certain cases of cancer. Secondly, physical activity has additional disease-specific merits in PD such as depression, sleep disturbances and constipation. These effects lead to raised quality of life. Furthermore, animal studies suggest that physical activity could slow down disease progression.

Simply informing patients about the importance of physical activity is not enough to initiate and maintain an adequate level of physical activity. We propose to develop a physical activity promoting program for sedentary patients with PD in order to raise their level of daily physical activity.

Objective: The first aim of the study is to investigate whether a physical activity promotion program will result in an increase in physical activity in sedentary patients with PD.

The second aim is to demonstrate an increase in physical fitness and quality of life.


Options:
A: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary Care | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Multidisciplinary Care; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
D: Arm Label: virtual reality balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: conventional balance training; Type: EXPERIMENTAL; Interventions: Behavioral: balance training | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: balance training; Assigned to Arm(s): conventional balance training, virtual reality balance training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis
Brief Summary: Study of the efficacy of rituximab for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of rituximab versus azathioprine


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): 2
C: Arm Label: Valaciclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valaciclovir | Arm Label: No additional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Valaciclovir; Assigned to Arm(s): Valaciclovir
D: Arm Label: Plasma Exchange with Standard Glucocorticoids; Type: EXPERIMENTAL; Interventions: Procedure: Plasma Exchange, Drug: Glucocorticoids [Standard Dose] | Arm Label: No Plasma Exchange with Standard Glucocorticoids; Type: ACTIVE_COMPARATOR; Interventions: Other: No Plasma Exchange, Drug: Glucocorticoids [Standard Dose] | Arm Label: Plasma Exchange with Reduced-Dose Glucocorticoids; Type: EXPERIMENTAL; Interventions: Procedure: Plasma Exchange, Drug: Glucocorticoids [Reduced Dose] | Arm Label: No Plasma Exchange with Reduced-Dose Glucocorticoids; Type: ACTIVE_COMPARATOR; Interventions: Other: No Plasma Exchange, Drug: Glucocorticoids [Reduced Dose] | Intervention Type: PROCEDURE; Name: Plasma Exchange; Assigned to Arm(s): Plasma Exchange with Reduced-Dose Glucocorticoids, Plasma Exchange with Standard Glucocorticoids | Intervention Type: OTHER; Name: No Plasma Exchange; Assigned to Arm(s): No Plasma Exchange with Reduced-Dose Glucocorticoids, No Plasma Exchange with Standard Glucocorticoids | Intervention Type: DRUG; Name: Glucocorticoids [Standard Dose]; Assigned to Arm(s): No Plasma Exchange with Standard Glucocorticoids, Plasma Exchange with Standard Glucocorticoids | Intervention Type: DRUG; Name: Glucocorticoids [Reduced Dose]; Assigned to Arm(s): No Plasma Exchange with Reduced-Dose Glucocorticoids, Plasma Exchange with Reduced-Dose Glucocorticoids

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Clinical Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor and Salivary Periodontal and Malodorous Bacteria Using for 7days
Brief Summary: Previous research has shown the oxidizing properties and microbiological efficacies of chlorine dioxide (ClO2). However, no clinical studies have investigated its microbiological efficacies on periodontal and malodorous bacteria. The aim of this study was to assess the inhibitory effects of a mouthwash containing ClO2 on morning oral malodor and on salivary periodontal and malodorous bacteria using for 7 days.


Options:
A: Arm Label: test; Type: EXPERIMENTAL; Interventions: Device: glycine powder air-polishing (Air-Flows)Perio Powder, Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Device: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) | Intervention Type: DEVICE; Name: glycine powder air-polishing (Air-Flows)Perio Powder; Assigned to Arm(s): test | Intervention Type: DEVICE; Name: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland); Assigned to Arm(s): control, test
B: Arm Label: group 1: drug; Type: EXPERIMENTAL; Interventions: Drug: group 1: drug: chlorine dioxide | Arm Label: group 2: device:; Type: EXPERIMENTAL; Interventions: Device: group 2: device: small tooth brush for tongue cleaning | Intervention Type: DRUG; Name: group 1: drug: chlorine dioxide; Assigned to Arm(s): group 1: drug | Intervention Type: DEVICE; Name: group 2: device: small tooth brush for tongue cleaning; Assigned to Arm(s): group 2: device:
C: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: Chlorine Dioxide; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder
Brief Summary: The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.


Options:
A: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine
B: Arm Label: GR205171; Type: EXPERIMENTAL; Interventions: Drug: NK1 Antagoist (GR205171), Procedure: Psychophysiology (Trauma Script), Procedure: Psychophysiology (Verbal Threat), Procedure: Psychophysiology (Fear Conditioning), Procedure: Psychophysiology (Affective Modulation), Procedure: Psychophysiology (Heart rate variability), Procedure: Lumbar Puncture, Procedure: 24-hour plasma sampling, Procedure: MRI | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Psychophysiology (Trauma Script), Procedure: Psychophysiology (Verbal Threat), Procedure: Psychophysiology (Fear Conditioning), Procedure: Psychophysiology (Affective Modulation), Procedure: Psychophysiology (Heart rate variability), Procedure: Lumbar Puncture, Procedure: 24-hour plasma sampling, Procedure: MRI | Intervention Type: DRUG; Name: NK1 Antagoist (GR205171); Assigned to Arm(s): GR205171 | Intervention Type: PROCEDURE; Name: Psychophysiology (Trauma Script); Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: Psychophysiology (Verbal Threat); Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: Psychophysiology (Fear Conditioning); Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: Psychophysiology (Affective Modulation); Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: Psychophysiology (Heart rate variability); Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: Lumbar Puncture; Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: 24-hour plasma sampling; Assigned to Arm(s): GR205171, placebo | Intervention Type: PROCEDURE; Name: MRI; Assigned to Arm(s): GR205171, placebo
C: Arm Label: N-Acetylcysteine; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N-Acetylcysteine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)
Brief Summary: This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload.

The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.


Options:
A: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
B: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
C: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)
Brief Summary: This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload.

The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.


Options:
A: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill
B: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
D: Arm Label: Thalassemia; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)
Brief Summary: This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload.

The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.


Options:
A: Arm Label: arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: DFP, DFO | Intervention Type: DRUG; Name: DFP (ferriprox) and deferasirox (ICL 670); Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: DFP, DFO; Assigned to Arm(s): arm 2
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Arm 1, Arm 3 | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Arm 2, Arm 3
D: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss in Primary Care: a Translation of the Diabetes Prevention Program
Brief Summary: The purpose of this study is to determine if primary care based, telephone-delivered weight loss interventions are effective.


Options:
A: Arm Label: Individual Telephone Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Individual telephone intervention | Arm Label: Group Telephone Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group telephone intervention | Intervention Type: BEHAVIORAL; Name: Individual telephone intervention; Assigned to Arm(s): Individual Telephone Intervention | Intervention Type: BEHAVIORAL; Name: Group telephone intervention; Assigned to Arm(s): Group Telephone Intervention
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Preceptorships; Type: EXPERIMENTAL; Interventions: Behavioral: 2-day preceptorship on obesity management | Intervention Type: BEHAVIORAL; Name: 2-day preceptorship on obesity management; Assigned to Arm(s): Preceptorships
C: Arm Label: Family Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Family Intervention | Arm Label: Motivational Interviewing; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral Family Intervention; Assigned to Arm(s): Family Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care

Answer: A